CA2604844A1 - Cancer-related genes - Google Patents
Cancer-related genes Download PDFInfo
- Publication number
- CA2604844A1 CA2604844A1 CA002604844A CA2604844A CA2604844A1 CA 2604844 A1 CA2604844 A1 CA 2604844A1 CA 002604844 A CA002604844 A CA 002604844A CA 2604844 A CA2604844 A CA 2604844A CA 2604844 A1 CA2604844 A1 CA 2604844A1
- Authority
- CA
- Canada
- Prior art keywords
- cancer
- gene
- antibody
- cell
- expression
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 108090000623 proteins and genes Proteins 0.000 title claims abstract description 439
- 206010028980 Neoplasm Diseases 0.000 title claims abstract description 328
- 201000011510 cancer Diseases 0.000 title claims abstract description 187
- 230000014509 gene expression Effects 0.000 claims abstract description 132
- 238000000034 method Methods 0.000 claims abstract description 91
- 102000004169 proteins and genes Human genes 0.000 claims abstract description 73
- -1 MET Proteins 0.000 claims description 109
- 108020004999 messenger RNA Proteins 0.000 claims description 105
- 229920001184 polypeptide Polymers 0.000 claims description 87
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 87
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 87
- 210000004027 cell Anatomy 0.000 claims description 82
- 210000001519 tissue Anatomy 0.000 claims description 76
- 238000003745 diagnosis Methods 0.000 claims description 69
- 208000026310 Breast neoplasm Diseases 0.000 claims description 52
- 101001123448 Homo sapiens Prolactin receptor Proteins 0.000 claims description 50
- 102100029000 Prolactin receptor Human genes 0.000 claims description 50
- 206010061535 Ovarian neoplasm Diseases 0.000 claims description 47
- 239000000523 sample Substances 0.000 claims description 46
- 206010046766 uterine cancer Diseases 0.000 claims description 45
- 101001055144 Homo sapiens Interleukin-2 receptor subunit alpha Proteins 0.000 claims description 41
- 101000899442 Homo sapiens Cadherin-23 Proteins 0.000 claims description 40
- 101001018097 Homo sapiens L-selectin Proteins 0.000 claims description 40
- 101000914514 Homo sapiens T-cell-specific surface glycoprotein CD28 Proteins 0.000 claims description 40
- 101000638886 Homo sapiens Urokinase-type plasminogen activator Proteins 0.000 claims description 40
- 102100026878 Interleukin-2 receptor subunit alpha Human genes 0.000 claims description 40
- 102100022509 Cadherin-23 Human genes 0.000 claims description 39
- 102100023600 Fibroblast growth factor receptor 2 Human genes 0.000 claims description 39
- 101000692259 Homo sapiens Phosphoprotein associated with glycosphingolipid-enriched microdomains 1 Proteins 0.000 claims description 39
- 101001077426 Homo sapiens Potassium voltage-gated channel subfamily H member 5 Proteins 0.000 claims description 39
- 101000611023 Homo sapiens Tumor necrosis factor receptor superfamily member 6 Proteins 0.000 claims description 39
- 101150091468 IGSF8 gene Proteins 0.000 claims description 39
- 102100036489 Immunoglobulin superfamily member 8 Human genes 0.000 claims description 39
- 102100033467 L-selectin Human genes 0.000 claims description 39
- 102100026066 Phosphoprotein associated with glycosphingolipid-enriched microdomains 1 Human genes 0.000 claims description 39
- 102100027213 T-cell-specific surface glycoprotein CD28 Human genes 0.000 claims description 39
- 102100040403 Tumor necrosis factor receptor superfamily member 6 Human genes 0.000 claims description 39
- 102100031358 Urokinase-type plasminogen activator Human genes 0.000 claims description 39
- 208000029742 colonic neoplasm Diseases 0.000 claims description 39
- 101000585551 Equus caballus Pregnancy-associated glycoprotein Proteins 0.000 claims description 38
- 101001130526 Homo sapiens Beta-1,3-N-acetylglucosaminyltransferase lunatic fringe Proteins 0.000 claims description 38
- 101001082627 Homo sapiens HLA class II histocompatibility antigen gamma chain Proteins 0.000 claims description 38
- 101001035232 Homo sapiens Integrin alpha-9 Proteins 0.000 claims description 38
- 101000852865 Homo sapiens Interferon alpha/beta receptor 2 Proteins 0.000 claims description 38
- 101001137975 Homo sapiens Leucyl-cystinyl aminopeptidase Proteins 0.000 claims description 38
- 101001124867 Homo sapiens Peroxiredoxin-1 Proteins 0.000 claims description 38
- 101000846336 Homo sapiens Ribitol-5-phosphate transferase FKTN Proteins 0.000 claims description 38
- 101000633786 Homo sapiens SLAM family member 6 Proteins 0.000 claims description 38
- 101000648507 Homo sapiens Tumor necrosis factor receptor superfamily member 14 Proteins 0.000 claims description 38
- 102100025071 Potassium voltage-gated channel subfamily H member 5 Human genes 0.000 claims description 38
- 102100029197 SLAM family member 6 Human genes 0.000 claims description 38
- 102100031403 Beta-1,3-N-acetylglucosaminyltransferase lunatic fringe Human genes 0.000 claims description 37
- 102100031510 Fibrillin-2 Human genes 0.000 claims description 37
- 102100028412 Fibroblast growth factor 10 Human genes 0.000 claims description 37
- 101710182389 Fibroblast growth factor receptor 2 Proteins 0.000 claims description 37
- 101710182396 Fibroblast growth factor receptor 3 Proteins 0.000 claims description 37
- 102100030595 HLA class II histocompatibility antigen gamma chain Human genes 0.000 claims description 37
- 101000866287 Homo sapiens Excitatory amino acid transporter 2 Proteins 0.000 claims description 37
- 101000846890 Homo sapiens Fibrillin-2 Proteins 0.000 claims description 37
- 101000917237 Homo sapiens Fibroblast growth factor 10 Proteins 0.000 claims description 37
- 101000764294 Homo sapiens Lymphotoxin-beta Proteins 0.000 claims description 37
- 101000954762 Homo sapiens Proto-oncogene Wnt-3 Proteins 0.000 claims description 37
- 101000934346 Homo sapiens T-cell surface antigen CD2 Proteins 0.000 claims description 37
- 101000679857 Homo sapiens Tumor necrosis factor receptor superfamily member 3 Proteins 0.000 claims description 37
- 102100039903 Integrin alpha-9 Human genes 0.000 claims description 37
- 102100036718 Interferon alpha/beta receptor 2 Human genes 0.000 claims description 37
- 102100020872 Leucyl-cystinyl aminopeptidase Human genes 0.000 claims description 37
- 102100026894 Lymphotoxin-beta Human genes 0.000 claims description 37
- 108010072582 Matrilin Proteins Proteins 0.000 claims description 37
- 102100031754 Ribitol-5-phosphate transferase FKTN Human genes 0.000 claims description 37
- 108091006626 SLC12A7 Proteins 0.000 claims description 37
- 102100034252 Solute carrier family 12 member 7 Human genes 0.000 claims description 37
- 102100035873 Tetraspanin-2 Human genes 0.000 claims description 37
- 101710151638 Tetraspanin-2 Proteins 0.000 claims description 37
- 102100033663 Transforming growth factor beta receptor type 3 Human genes 0.000 claims description 37
- 102100028785 Tumor necrosis factor receptor superfamily member 14 Human genes 0.000 claims description 37
- 102100022156 Tumor necrosis factor receptor superfamily member 3 Human genes 0.000 claims description 37
- 108010079292 betaglycan Proteins 0.000 claims description 37
- 108090000007 Carboxypeptidase M Proteins 0.000 claims description 36
- 102100028072 Fibroblast growth factor 4 Human genes 0.000 claims description 36
- 102100027842 Fibroblast growth factor receptor 3 Human genes 0.000 claims description 36
- 101001027382 Homo sapiens Fibroblast growth factor 8 Proteins 0.000 claims description 36
- 101000994375 Homo sapiens Integrin alpha-4 Proteins 0.000 claims description 36
- 101001043809 Homo sapiens Interleukin-7 receptor subunit alpha Proteins 0.000 claims description 36
- 101000825960 Homo sapiens R-spondin-3 Proteins 0.000 claims description 36
- 102100021593 Interleukin-7 receptor subunit alpha Human genes 0.000 claims description 36
- 102100033669 Matrilin-2 Human genes 0.000 claims description 36
- 102000012980 SLC1A2 Human genes 0.000 claims description 36
- 108091006660 SLC9A9 Proteins 0.000 claims description 36
- 102100029967 Sodium/hydrogen exchanger 9 Human genes 0.000 claims description 36
- 102100025237 T-cell surface antigen CD2 Human genes 0.000 claims description 36
- 102000052549 Wnt-3 Human genes 0.000 claims description 36
- 102100031585 ADP-ribosyl cyclase/cyclic ADP-ribose hydrolase 1 Human genes 0.000 claims description 35
- 102100032936 Carboxypeptidase M Human genes 0.000 claims description 35
- 102100037680 Fibroblast growth factor 8 Human genes 0.000 claims description 35
- 101000777636 Homo sapiens ADP-ribosyl cyclase/cyclic ADP-ribose hydrolase 1 Proteins 0.000 claims description 35
- 101000940120 Homo sapiens Collagen alpha-1(XIX) chain Proteins 0.000 claims description 35
- 101000899935 Homo sapiens Collagen alpha-1(XV) chain Proteins 0.000 claims description 35
- 101001060280 Homo sapiens Fibroblast growth factor 3 Proteins 0.000 claims description 35
- 101001060274 Homo sapiens Fibroblast growth factor 4 Proteins 0.000 claims description 35
- 101000932478 Homo sapiens Receptor-type tyrosine-protein kinase FLT3 Proteins 0.000 claims description 35
- 101000591201 Homo sapiens Receptor-type tyrosine-protein phosphatase kappa Proteins 0.000 claims description 35
- 101000851376 Homo sapiens Tumor necrosis factor receptor superfamily member 8 Proteins 0.000 claims description 35
- 101000841325 Homo sapiens Urotensin-2 Proteins 0.000 claims description 35
- 102100032818 Integrin alpha-4 Human genes 0.000 claims description 35
- 102100022766 R-spondin-3 Human genes 0.000 claims description 35
- 102100020718 Receptor-type tyrosine-protein kinase FLT3 Human genes 0.000 claims description 35
- 102100034089 Receptor-type tyrosine-protein phosphatase kappa Human genes 0.000 claims description 35
- 108091006263 SLC4A8 Proteins 0.000 claims description 35
- 102000006633 Sodium-Bicarbonate Symporters Human genes 0.000 claims description 35
- 102100036857 Tumor necrosis factor receptor superfamily member 8 Human genes 0.000 claims description 35
- 102100029097 Urotensin-2 Human genes 0.000 claims description 35
- 108700013515 Wnt3A Proteins 0.000 claims description 35
- 101150068520 wnt3a gene Proteins 0.000 claims description 35
- 102100034613 Annexin A2 Human genes 0.000 claims description 34
- 102100027314 Beta-2-microglobulin Human genes 0.000 claims description 34
- 102100031161 Collagen alpha-1(XIX) chain Human genes 0.000 claims description 34
- 102100022640 Collagen alpha-1(XV) chain Human genes 0.000 claims description 34
- 102100036411 Dermatopontin Human genes 0.000 claims description 34
- 102100028043 Fibroblast growth factor 3 Human genes 0.000 claims description 34
- 101000924474 Homo sapiens Annexin A2 Proteins 0.000 claims description 34
- 101000937544 Homo sapiens Beta-2-microglobulin Proteins 0.000 claims description 34
- 101000929047 Homo sapiens Dermatopontin Proteins 0.000 claims description 34
- 101001010600 Homo sapiens Interleukin-12 subunit alpha Proteins 0.000 claims description 34
- 101001033312 Homo sapiens Interleukin-4 receptor subunit alpha Proteins 0.000 claims description 34
- 101001126417 Homo sapiens Platelet-derived growth factor receptor alpha Proteins 0.000 claims description 34
- 101000781955 Homo sapiens Proto-oncogene Wnt-1 Proteins 0.000 claims description 34
- 101000753197 Homo sapiens Sodium/potassium-transporting ATPase subunit alpha-2 Proteins 0.000 claims description 34
- 102100030698 Interleukin-12 subunit alpha Human genes 0.000 claims description 34
- 102100039078 Interleukin-4 receptor subunit alpha Human genes 0.000 claims description 34
- 102100025246 Neurogenic locus notch homolog protein 2 Human genes 0.000 claims description 34
- 108010029751 Notch2 Receptor Proteins 0.000 claims description 34
- 102100030485 Platelet-derived growth factor receptor alpha Human genes 0.000 claims description 34
- 102100021253 Antileukoproteinase Human genes 0.000 claims description 33
- 101000615334 Homo sapiens Antileukoproteinase Proteins 0.000 claims description 33
- 101000599048 Homo sapiens Interleukin-6 receptor subunit alpha Proteins 0.000 claims description 33
- 101000955355 Homo sapiens Xylosyltransferase 1 Proteins 0.000 claims description 33
- 102100037792 Interleukin-6 receptor subunit alpha Human genes 0.000 claims description 33
- 108091006529 SLC28A2 Proteins 0.000 claims description 33
- 102100021541 Sodium/nucleoside cotransporter 2 Human genes 0.000 claims description 33
- 102100021955 Sodium/potassium-transporting ATPase subunit alpha-2 Human genes 0.000 claims description 33
- 101000879712 Streptomyces lividans Protease inhibitor Proteins 0.000 claims description 33
- 102000052547 Wnt-1 Human genes 0.000 claims description 33
- 102100038983 Xylosyltransferase 1 Human genes 0.000 claims description 33
- 206010006187 Breast cancer Diseases 0.000 claims description 32
- 101000800116 Homo sapiens Thy-1 membrane glycoprotein Proteins 0.000 claims description 32
- 101000638255 Homo sapiens Tumor necrosis factor ligand superfamily member 8 Proteins 0.000 claims description 32
- 101000763003 Homo sapiens Two pore channel protein 1 Proteins 0.000 claims description 32
- 102100032100 Tumor necrosis factor ligand superfamily member 8 Human genes 0.000 claims description 32
- 208000014018 liver neoplasm Diseases 0.000 claims description 32
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims description 31
- 102100033523 Thy-1 membrane glycoprotein Human genes 0.000 claims description 31
- 102100026736 Two pore channel protein 1 Human genes 0.000 claims description 31
- 101710182386 Fibroblast growth factor receptor 1 Proteins 0.000 claims description 30
- 208000008839 Kidney Neoplasms Diseases 0.000 claims description 30
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims description 30
- 230000001926 lymphatic effect Effects 0.000 claims description 30
- ZEOWTGPWHLSLOG-UHFFFAOYSA-N Cc1ccc(cc1-c1ccc2c(n[nH]c2c1)-c1cnn(c1)C1CC1)C(=O)Nc1cccc(c1)C(F)(F)F Chemical compound Cc1ccc(cc1-c1ccc2c(n[nH]c2c1)-c1cnn(c1)C1CC1)C(=O)Nc1cccc(c1)C(F)(F)F ZEOWTGPWHLSLOG-UHFFFAOYSA-N 0.000 claims description 29
- 102100023593 Fibroblast growth factor receptor 1 Human genes 0.000 claims description 29
- 101000879840 Homo sapiens Serglycin Proteins 0.000 claims description 29
- 206010033128 Ovarian cancer Diseases 0.000 claims description 29
- 206010060862 Prostate cancer Diseases 0.000 claims description 29
- 208000000453 Skin Neoplasms Diseases 0.000 claims description 29
- 201000002528 pancreatic cancer Diseases 0.000 claims description 29
- 101000999079 Homo sapiens Radiation-inducible immediate-early gene IEX-1 Proteins 0.000 claims description 28
- 101000584583 Homo sapiens Receptor activity-modifying protein 1 Proteins 0.000 claims description 28
- 102100030697 Receptor activity-modifying protein 1 Human genes 0.000 claims description 28
- 208000002495 Uterine Neoplasms Diseases 0.000 claims description 28
- 150000007523 nucleic acids Chemical class 0.000 claims description 28
- 101000830603 Homo sapiens Tumor necrosis factor ligand superfamily member 11 Proteins 0.000 claims description 26
- 102000039446 nucleic acids Human genes 0.000 claims description 26
- 108020004707 nucleic acids Proteins 0.000 claims description 26
- 206010009944 Colon cancer Diseases 0.000 claims description 25
- 102100024568 Tumor necrosis factor ligand superfamily member 11 Human genes 0.000 claims description 25
- 102100023181 Neurogenic locus notch homolog protein 1 Human genes 0.000 claims description 24
- 108010029755 Notch1 Receptor Proteins 0.000 claims description 24
- 239000012472 biological sample Substances 0.000 claims description 24
- 201000007270 liver cancer Diseases 0.000 claims description 23
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims description 22
- 206010038389 Renal cancer Diseases 0.000 claims description 22
- 239000002246 antineoplastic agent Substances 0.000 claims description 22
- 210000000481 breast Anatomy 0.000 claims description 22
- 201000010881 cervical cancer Diseases 0.000 claims description 22
- 201000010982 kidney cancer Diseases 0.000 claims description 22
- 201000005202 lung cancer Diseases 0.000 claims description 22
- 208000020816 lung neoplasm Diseases 0.000 claims description 22
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims description 22
- 208000008443 pancreatic carcinoma Diseases 0.000 claims description 22
- 206010008342 Cervix carcinoma Diseases 0.000 claims description 21
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 claims description 21
- 102000040430 polynucleotide Human genes 0.000 claims description 21
- 108091033319 polynucleotide Proteins 0.000 claims description 21
- 239000002157 polynucleotide Substances 0.000 claims description 21
- 201000000849 skin cancer Diseases 0.000 claims description 21
- 210000001072 colon Anatomy 0.000 claims description 17
- 208000005718 Stomach Neoplasms Diseases 0.000 claims description 16
- 206010017758 gastric cancer Diseases 0.000 claims description 16
- 201000011549 stomach cancer Diseases 0.000 claims description 16
- 101001117312 Homo sapiens Programmed cell death 1 ligand 2 Proteins 0.000 claims description 15
- 102100024213 Programmed cell death 1 ligand 2 Human genes 0.000 claims description 15
- 239000012634 fragment Substances 0.000 claims description 12
- 239000000203 mixture Substances 0.000 claims description 12
- 238000009739 binding Methods 0.000 claims description 11
- 206010005003 Bladder cancer Diseases 0.000 claims description 10
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 claims description 10
- 201000001441 melanoma Diseases 0.000 claims description 10
- 239000002773 nucleotide Substances 0.000 claims description 10
- 125000003729 nucleotide group Chemical group 0.000 claims description 10
- 239000013610 patient sample Substances 0.000 claims description 10
- 201000005112 urinary bladder cancer Diseases 0.000 claims description 10
- 108091034117 Oligonucleotide Proteins 0.000 claims description 9
- 230000001093 anti-cancer Effects 0.000 claims description 8
- 239000000427 antigen Substances 0.000 claims description 8
- 108091007433 antigens Proteins 0.000 claims description 8
- 102000036639 antigens Human genes 0.000 claims description 8
- 230000001965 increasing effect Effects 0.000 claims description 8
- 238000011282 treatment Methods 0.000 claims description 8
- 210000004881 tumor cell Anatomy 0.000 claims description 8
- 230000008859 change Effects 0.000 claims description 7
- 238000001514 detection method Methods 0.000 claims description 6
- 239000003814 drug Substances 0.000 claims description 5
- 229940127121 immunoconjugate Drugs 0.000 claims description 5
- 210000002784 stomach Anatomy 0.000 claims description 5
- 241000124008 Mammalia Species 0.000 claims description 4
- 108020004711 Nucleic Acid Probes Proteins 0.000 claims description 4
- 239000003153 chemical reaction reagent Substances 0.000 claims description 4
- 239000012216 imaging agent Substances 0.000 claims description 4
- 230000005764 inhibitory process Effects 0.000 claims description 4
- 239000002853 nucleic acid probe Substances 0.000 claims description 4
- 238000012216 screening Methods 0.000 claims description 4
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 claims description 3
- 210000001672 ovary Anatomy 0.000 claims description 3
- 230000002018 overexpression Effects 0.000 claims description 3
- 230000009467 reduction Effects 0.000 claims description 3
- 230000004614 tumor growth Effects 0.000 claims description 3
- 108010054477 Immunoglobulin Fab Fragments Proteins 0.000 claims description 2
- 102000001706 Immunoglobulin Fab Fragments Human genes 0.000 claims description 2
- 239000000074 antisense oligonucleotide Substances 0.000 claims description 2
- 238000012230 antisense oligonucleotides Methods 0.000 claims description 2
- 210000003443 bladder cell Anatomy 0.000 claims description 2
- 150000002484 inorganic compounds Chemical class 0.000 claims description 2
- 229910010272 inorganic material Inorganic materials 0.000 claims description 2
- 210000003292 kidney cell Anatomy 0.000 claims description 2
- 210000005229 liver cell Anatomy 0.000 claims description 2
- 210000005265 lung cell Anatomy 0.000 claims description 2
- 230000003472 neutralizing effect Effects 0.000 claims description 2
- 150000002894 organic compounds Chemical class 0.000 claims description 2
- 210000000496 pancreas Anatomy 0.000 claims description 2
- 210000005267 prostate cell Anatomy 0.000 claims description 2
- 210000004927 skin cell Anatomy 0.000 claims description 2
- 102100030368 Phospholipid phosphatase-related protein type 4 Human genes 0.000 claims 12
- 102000044880 Wnt3A Human genes 0.000 claims 12
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 230000002222 downregulating effect Effects 0.000 abstract 1
- 230000010354 integration Effects 0.000 description 70
- 235000018102 proteins Nutrition 0.000 description 68
- 230000002596 correlated effect Effects 0.000 description 67
- 238000002560 therapeutic procedure Methods 0.000 description 63
- 241000714177 Murine leukemia virus Species 0.000 description 61
- 239000000047 product Substances 0.000 description 47
- 101000883798 Homo sapiens Probable ATP-dependent RNA helicase DDX53 Proteins 0.000 description 32
- 102100038236 Probable ATP-dependent RNA helicase DDX53 Human genes 0.000 description 32
- 238000000692 Student's t-test Methods 0.000 description 27
- 238000012353 t test Methods 0.000 description 27
- 208000025855 muscular dystrophy-dystroglycanopathy (congenital with brain and eye anomalies), type A, 4 Diseases 0.000 description 25
- 102100037051 Protein Wnt-3a Human genes 0.000 description 23
- 208000025421 tumor of uterus Diseases 0.000 description 18
- 102000052575 Proto-Oncogene Human genes 0.000 description 17
- 108700020978 Proto-Oncogene Proteins 0.000 description 17
- 102100037344 Serglycin Human genes 0.000 description 16
- 230000002103 transcriptional effect Effects 0.000 description 16
- 208000023958 prostate neoplasm Diseases 0.000 description 15
- 230000010056 antibody-dependent cellular cytotoxicity Effects 0.000 description 14
- 230000000694 effects Effects 0.000 description 14
- 230000035772 mutation Effects 0.000 description 14
- 108020003175 receptors Proteins 0.000 description 14
- 230000002611 ovarian Effects 0.000 description 13
- 102000005962 receptors Human genes 0.000 description 13
- 239000003795 chemical substances by application Substances 0.000 description 12
- 238000003780 insertion Methods 0.000 description 11
- 230000037431 insertion Effects 0.000 description 11
- 208000037841 lung tumor Diseases 0.000 description 11
- 206010025323 Lymphomas Diseases 0.000 description 10
- 210000004072 lung Anatomy 0.000 description 10
- 206010019695 Hepatic neoplasm Diseases 0.000 description 9
- 210000004185 liver Anatomy 0.000 description 9
- 210000003491 skin Anatomy 0.000 description 9
- 206010029098 Neoplasm skin Diseases 0.000 description 8
- 230000007423 decrease Effects 0.000 description 8
- 210000002307 prostate Anatomy 0.000 description 8
- 241001430294 unidentified retrovirus Species 0.000 description 8
- 208000024719 uterine cervix neoplasm Diseases 0.000 description 8
- 230000027455 binding Effects 0.000 description 7
- 102000003675 cytokine receptors Human genes 0.000 description 7
- 108010057085 cytokine receptors Proteins 0.000 description 7
- 208000032839 leukemia Diseases 0.000 description 7
- 239000013615 primer Substances 0.000 description 7
- 108020004414 DNA Proteins 0.000 description 6
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 description 6
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 description 6
- 108700020796 Oncogene Proteins 0.000 description 6
- 150000001875 compounds Chemical class 0.000 description 6
- 201000010099 disease Diseases 0.000 description 6
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 6
- 210000003734 kidney Anatomy 0.000 description 6
- 230000001225 therapeutic effect Effects 0.000 description 6
- 206010061968 Gastric neoplasm Diseases 0.000 description 5
- 241000699670 Mus sp. Species 0.000 description 5
- 102000043276 Oncogene Human genes 0.000 description 5
- 241000700605 Viruses Species 0.000 description 5
- 230000015572 biosynthetic process Effects 0.000 description 5
- 230000000295 complement effect Effects 0.000 description 5
- 230000007246 mechanism Effects 0.000 description 5
- 230000001566 pro-viral effect Effects 0.000 description 5
- 210000002966 serum Anatomy 0.000 description 5
- 238000006467 substitution reaction Methods 0.000 description 5
- 230000004083 survival effect Effects 0.000 description 5
- 108010078791 Carrier Proteins Proteins 0.000 description 4
- 101000764535 Homo sapiens Lymphotoxin-alpha Proteins 0.000 description 4
- 102100026238 Lymphotoxin-alpha Human genes 0.000 description 4
- 241001465754 Metazoa Species 0.000 description 4
- 102000004278 Receptor Protein-Tyrosine Kinases Human genes 0.000 description 4
- 108090000873 Receptor Protein-Tyrosine Kinases Proteins 0.000 description 4
- 238000004458 analytical method Methods 0.000 description 4
- 231100000504 carcinogenesis Toxicity 0.000 description 4
- 230000010261 cell growth Effects 0.000 description 4
- 230000001404 mediated effect Effects 0.000 description 4
- 210000000056 organ Anatomy 0.000 description 4
- 230000000704 physical effect Effects 0.000 description 4
- 230000001105 regulatory effect Effects 0.000 description 4
- 102000014914 Carrier Proteins Human genes 0.000 description 3
- 102000004127 Cytokines Human genes 0.000 description 3
- 108090000695 Cytokines Proteins 0.000 description 3
- 108700025695 Suppressor Genes Proteins 0.000 description 3
- 230000003321 amplification Effects 0.000 description 3
- 238000012217 deletion Methods 0.000 description 3
- 230000037430 deletion Effects 0.000 description 3
- 230000001419 dependent effect Effects 0.000 description 3
- 239000012530 fluid Substances 0.000 description 3
- 230000013595 glycosylation Effects 0.000 description 3
- 238000006206 glycosylation reaction Methods 0.000 description 3
- 230000012010 growth Effects 0.000 description 3
- 238000009169 immunotherapy Methods 0.000 description 3
- 238000000338 in vitro Methods 0.000 description 3
- 238000002493 microarray Methods 0.000 description 3
- 238000003199 nucleic acid amplification method Methods 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- 230000011664 signaling Effects 0.000 description 3
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 2
- 201000010028 Acrocephalosyndactylia Diseases 0.000 description 2
- 208000005623 Carcinogenesis Diseases 0.000 description 2
- 102000053602 DNA Human genes 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- 108010087819 Fc receptors Proteins 0.000 description 2
- 102000009109 Fc receptors Human genes 0.000 description 2
- 108090000381 Fibroblast growth factor 4 Proteins 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- 101000827688 Homo sapiens Fibroblast growth factor receptor 2 Proteins 0.000 description 2
- 102100026120 IgG receptor FcRn large subunit p51 Human genes 0.000 description 2
- 101710177940 IgG receptor FcRn large subunit p51 Proteins 0.000 description 2
- 108010091221 Lymphotoxin beta Receptor Proteins 0.000 description 2
- 108090000362 Lymphotoxin-beta Proteins 0.000 description 2
- 206010027476 Metastases Diseases 0.000 description 2
- 241000699666 Mus <mouse, genus> Species 0.000 description 2
- 108010070047 Notch Receptors Proteins 0.000 description 2
- 201000004014 Pfeiffer syndrome Diseases 0.000 description 2
- 206010057249 Phagocytosis Diseases 0.000 description 2
- 241000700159 Rattus Species 0.000 description 2
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 2
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 2
- 206010053613 Type IV hypersensitivity reaction Diseases 0.000 description 2
- DZBUGLKDJFMEHC-UHFFFAOYSA-N acridine Chemical compound C1=CC=CC2=CC3=CC=CC=C3N=C21 DZBUGLKDJFMEHC-UHFFFAOYSA-N 0.000 description 2
- 238000007792 addition Methods 0.000 description 2
- 125000003275 alpha amino acid group Chemical group 0.000 description 2
- 235000001014 amino acid Nutrition 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- 230000036952 cancer formation Effects 0.000 description 2
- 230000022534 cell killing Effects 0.000 description 2
- 230000012292 cell migration Effects 0.000 description 2
- 230000009087 cell motility Effects 0.000 description 2
- 230000004663 cell proliferation Effects 0.000 description 2
- 125000003636 chemical group Chemical group 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 238000002512 chemotherapy Methods 0.000 description 2
- 239000013068 control sample Substances 0.000 description 2
- 230000000875 corresponding effect Effects 0.000 description 2
- 230000009089 cytolysis Effects 0.000 description 2
- 231100000433 cytotoxic Toxicity 0.000 description 2
- 230000001472 cytotoxic effect Effects 0.000 description 2
- 239000012636 effector Substances 0.000 description 2
- 239000003623 enhancer Substances 0.000 description 2
- 229940088598 enzyme Drugs 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 210000004602 germ cell Anatomy 0.000 description 2
- 230000001976 improved effect Effects 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 239000000411 inducer Substances 0.000 description 2
- 102000006495 integrins Human genes 0.000 description 2
- 108010044426 integrins Proteins 0.000 description 2
- 125000005647 linker group Chemical group 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- 229910052751 metal Inorganic materials 0.000 description 2
- 239000002184 metal Substances 0.000 description 2
- 150000002739 metals Chemical class 0.000 description 2
- 230000009401 metastasis Effects 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 238000010172 mouse model Methods 0.000 description 2
- 230000008782 phagocytosis Effects 0.000 description 2
- 230000003389 potentiating effect Effects 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- ZCCUUQDIBDJBTK-UHFFFAOYSA-N psoralen Chemical compound C1=C2OC(=O)C=CC2=CC2=C1OC=C2 ZCCUUQDIBDJBTK-UHFFFAOYSA-N 0.000 description 2
- 230000005855 radiation Effects 0.000 description 2
- 241000894007 species Species 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 239000000758 substrate Substances 0.000 description 2
- 238000013518 transcription Methods 0.000 description 2
- 230000035897 transcription Effects 0.000 description 2
- 239000013598 vector Substances 0.000 description 2
- VXGRJERITKFWPL-UHFFFAOYSA-N 4',5'-Dihydropsoralen Natural products C1=C2OC(=O)C=CC2=CC2=C1OCC2 VXGRJERITKFWPL-UHFFFAOYSA-N 0.000 description 1
- 241000714186 AKR (endogenous) murine leukemia virus Species 0.000 description 1
- 108091006112 ATPases Proteins 0.000 description 1
- 206010069754 Acquired gene mutation Diseases 0.000 description 1
- 102000057290 Adenosine Triphosphatases Human genes 0.000 description 1
- 102000004400 Aminopeptidases Human genes 0.000 description 1
- 108090000915 Aminopeptidases Proteins 0.000 description 1
- 108090000668 Annexin A2 Proteins 0.000 description 1
- 101710170230 Antimicrobial peptide 1 Proteins 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 108050007957 Cadherin Proteins 0.000 description 1
- 102000000905 Cadherin Human genes 0.000 description 1
- 102000055006 Calcitonin Human genes 0.000 description 1
- 108060001064 Calcitonin Proteins 0.000 description 1
- 108090000312 Calcium Channels Proteins 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- 108010006303 Carboxypeptidases Proteins 0.000 description 1
- 102000005367 Carboxypeptidases Human genes 0.000 description 1
- 108090000994 Catalytic RNA Proteins 0.000 description 1
- 102000053642 Catalytic RNA Human genes 0.000 description 1
- 108010078140 Cation Transport Proteins Proteins 0.000 description 1
- 241000700198 Cavia Species 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
- 206010008723 Chondrodystrophy Diseases 0.000 description 1
- 108091026890 Coding region Proteins 0.000 description 1
- 108010035532 Collagen Proteins 0.000 description 1
- 102000008186 Collagen Human genes 0.000 description 1
- 206010066946 Craniofacial dysostosis Diseases 0.000 description 1
- 241000699800 Cricetinae Species 0.000 description 1
- 239000004971 Cross linker Substances 0.000 description 1
- 201000006526 Crouzon syndrome Diseases 0.000 description 1
- SHZGCJCMOBCMKK-UHFFFAOYSA-N D-mannomethylose Natural products CC1OC(O)C(O)C(O)C1O SHZGCJCMOBCMKK-UHFFFAOYSA-N 0.000 description 1
- 238000000018 DNA microarray Methods 0.000 description 1
- 239000003155 DNA primer Substances 0.000 description 1
- 102000016928 DNA-directed DNA polymerase Human genes 0.000 description 1
- 108010014303 DNA-directed DNA polymerase Proteins 0.000 description 1
- 102000004163 DNA-directed RNA polymerases Human genes 0.000 description 1
- 108090000626 DNA-directed RNA polymerases Proteins 0.000 description 1
- 102100031780 Endonuclease Human genes 0.000 description 1
- 108010042407 Endonucleases Proteins 0.000 description 1
- 102000004533 Endonucleases Human genes 0.000 description 1
- 241000283086 Equidae Species 0.000 description 1
- 208000035126 Facies Diseases 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 108010030242 Fibrillin-2 Proteins 0.000 description 1
- 108090001047 Fibroblast growth factor 10 Proteins 0.000 description 1
- 102100024785 Fibroblast growth factor 2 Human genes 0.000 description 1
- 102000010453 Folate receptor gamma Human genes 0.000 description 1
- 108050001933 Folate receptor gamma Proteins 0.000 description 1
- PNNNRSAQSRJVSB-SLPGGIOYSA-N Fucose Natural products C[C@H](O)[C@@H](O)[C@H](O)[C@H](O)C=O PNNNRSAQSRJVSB-SLPGGIOYSA-N 0.000 description 1
- 102100022623 Hepatocyte growth factor receptor Human genes 0.000 description 1
- 101001052035 Homo sapiens Fibroblast growth factor 2 Proteins 0.000 description 1
- 101000972946 Homo sapiens Hepatocyte growth factor receptor Proteins 0.000 description 1
- 101000999311 Homo sapiens Immunoglobulin superfamily member 8 Proteins 0.000 description 1
- 101000954805 Homo sapiens Protein Wnt-3a Proteins 0.000 description 1
- 101000863706 Homo sapiens Sodium/hydrogen exchanger 9 Proteins 0.000 description 1
- 101000800821 Homo sapiens Transforming growth factor beta receptor type 3 Proteins 0.000 description 1
- 101001052849 Homo sapiens Tyrosine-protein kinase Fer Proteins 0.000 description 1
- 208000026350 Inborn Genetic disease Diseases 0.000 description 1
- 108010038486 Interleukin-4 Receptors Proteins 0.000 description 1
- 108010038498 Interleukin-7 Receptors Proteins 0.000 description 1
- 108090000862 Ion Channels Proteins 0.000 description 1
- 102000004310 Ion Channels Human genes 0.000 description 1
- 208000009289 Jackson-Weiss syndrome Diseases 0.000 description 1
- SHZGCJCMOBCMKK-DHVFOXMCSA-N L-fucopyranose Chemical compound C[C@@H]1OC(O)[C@@H](O)[C@H](O)[C@@H]1O SHZGCJCMOBCMKK-DHVFOXMCSA-N 0.000 description 1
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 1
- 102000018170 Lymphotoxin beta Receptor Human genes 0.000 description 1
- 102000003959 Lymphotoxin-beta Human genes 0.000 description 1
- 108010006519 Molecular Chaperones Proteins 0.000 description 1
- 102000005431 Molecular Chaperones Human genes 0.000 description 1
- 108091006315 Na+/HCO3 − co-transport proteins Proteins 0.000 description 1
- 102100032028 Non-receptor tyrosine-protein kinase TYK2 Human genes 0.000 description 1
- 101710163270 Nuclease Proteins 0.000 description 1
- 108091028043 Nucleic acid sequence Proteins 0.000 description 1
- 108091005461 Nucleic proteins Proteins 0.000 description 1
- 108700026244 Open Reading Frames Proteins 0.000 description 1
- BPQQTUXANYXVAA-UHFFFAOYSA-N Orthosilicate Chemical compound [O-][Si]([O-])([O-])[O-] BPQQTUXANYXVAA-UHFFFAOYSA-N 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 102000035195 Peptidases Human genes 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- 108010089430 Phosphoproteins Proteins 0.000 description 1
- 102000004160 Phosphoric Monoester Hydrolases Human genes 0.000 description 1
- 108090000608 Phosphoric Monoester Hydrolases Proteins 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 102000004257 Potassium Channel Human genes 0.000 description 1
- 241000288906 Primates Species 0.000 description 1
- 108700030875 Programmed Cell Death 1 Ligand 2 Proteins 0.000 description 1
- 108010002519 Prolactin Receptors Proteins 0.000 description 1
- 239000004365 Protease Substances 0.000 description 1
- 108010029485 Protein Isoforms Proteins 0.000 description 1
- 102000001708 Protein Isoforms Human genes 0.000 description 1
- 108010076504 Protein Sorting Signals Proteins 0.000 description 1
- 102000016611 Proteoglycans Human genes 0.000 description 1
- 108010067787 Proteoglycans Proteins 0.000 description 1
- 108010089836 Proto-Oncogene Proteins c-met Proteins 0.000 description 1
- 238000012228 RNA interference-mediated gene silencing Methods 0.000 description 1
- 108010092799 RNA-directed DNA polymerase Proteins 0.000 description 1
- 108091028664 Ribonucleotide Proteins 0.000 description 1
- 241000283984 Rodentia Species 0.000 description 1
- 101710083278 SLAM family member 6 Proteins 0.000 description 1
- 108091006207 SLC-Transporter Proteins 0.000 description 1
- 108010071390 Serum Albumin Proteins 0.000 description 1
- 102000007562 Serum Albumin Human genes 0.000 description 1
- BLRPTPMANUNPDV-UHFFFAOYSA-N Silane Chemical compound [SiH4] BLRPTPMANUNPDV-UHFFFAOYSA-N 0.000 description 1
- 108020004682 Single-Stranded DNA Proteins 0.000 description 1
- 108020004459 Small interfering RNA Proteins 0.000 description 1
- 102000047177 Sodium bicarbonate cotransporters Human genes 0.000 description 1
- 108010074941 Sodium-Potassium-Chloride Symporters Proteins 0.000 description 1
- 241000282887 Suidae Species 0.000 description 1
- 101000987219 Sus scrofa Pregnancy-associated glycoprotein 1 Proteins 0.000 description 1
- 108010010057 TYK2 Kinase Proteins 0.000 description 1
- 108700031126 Tetraspanins Proteins 0.000 description 1
- 102000043977 Tetraspanins Human genes 0.000 description 1
- 206010049808 Thanatophoric dwarfism Diseases 0.000 description 1
- RYYWUUFWQRZTIU-UHFFFAOYSA-N Thiophosphoric acid Chemical class OP(O)(S)=O RYYWUUFWQRZTIU-UHFFFAOYSA-N 0.000 description 1
- 102100024537 Tyrosine-protein kinase Fer Human genes 0.000 description 1
- 101710095163 Urotensin-2 Proteins 0.000 description 1
- 241000251539 Vertebrata <Metazoa> Species 0.000 description 1
- 108700005077 Viral Genes Proteins 0.000 description 1
- 108050007995 Xylosyltransferase 1 Proteins 0.000 description 1
- 238000010317 ablation therapy Methods 0.000 description 1
- 208000008919 achondroplasia Diseases 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 239000000556 agonist Substances 0.000 description 1
- 239000002168 alkylating agent Substances 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 239000005557 antagonist Substances 0.000 description 1
- 230000000692 anti-sense effect Effects 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- 238000011319 anticancer therapy Methods 0.000 description 1
- 230000000890 antigenic effect Effects 0.000 description 1
- 229940041181 antineoplastic drug Drugs 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 239000011324 bead Substances 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 108010081355 beta 2-Microglobulin Proteins 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000000601 blood cell Anatomy 0.000 description 1
- 238000006664 bond formation reaction Methods 0.000 description 1
- BBBFJLBPOGFECG-VJVYQDLKSA-N calcitonin Chemical compound N([C@H](C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H]([C@@H](C)O)C(=O)N1[C@@H](CCC1)C(N)=O)C(C)C)C(=O)[C@@H]1CSSC[C@H](N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1 BBBFJLBPOGFECG-VJVYQDLKSA-N 0.000 description 1
- 229960004015 calcitonin Drugs 0.000 description 1
- 230000009702 cancer cell proliferation Effects 0.000 description 1
- 150000001720 carbohydrates Chemical group 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 210000003679 cervix uteri Anatomy 0.000 description 1
- 239000002738 chelating agent Substances 0.000 description 1
- 230000000973 chemotherapeutic effect Effects 0.000 description 1
- 238000010367 cloning Methods 0.000 description 1
- 229920001436 collagen Polymers 0.000 description 1
- 239000002299 complementary DNA Substances 0.000 description 1
- 208000009854 congenital contractural arachnodactyly Diseases 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 125000000151 cysteine group Chemical group N[C@@H](CS)C(=O)* 0.000 description 1
- 229940127089 cytotoxic agent Drugs 0.000 description 1
- 230000003013 cytotoxicity Effects 0.000 description 1
- 231100000135 cytotoxicity Toxicity 0.000 description 1
- 239000005547 deoxyribonucleotide Substances 0.000 description 1
- 125000002637 deoxyribonucleotide group Chemical group 0.000 description 1
- 230000009274 differential gene expression Effects 0.000 description 1
- 238000010494 dissociation reaction Methods 0.000 description 1
- 230000005593 dissociations Effects 0.000 description 1
- NAGJZTKCGNOGPW-UHFFFAOYSA-N dithiophosphoric acid Chemical class OP(O)(S)=S NAGJZTKCGNOGPW-UHFFFAOYSA-N 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 238000009510 drug design Methods 0.000 description 1
- 238000007876 drug discovery Methods 0.000 description 1
- 230000009977 dual effect Effects 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 108010052621 fas Receptor Proteins 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 229960003297 gemtuzumab ozogamicin Drugs 0.000 description 1
- 230000009368 gene silencing by RNA Effects 0.000 description 1
- 208000016361 genetic disease Diseases 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 150000002339 glycosphingolipids Chemical class 0.000 description 1
- 229940022353 herceptin Drugs 0.000 description 1
- 230000003054 hormonal effect Effects 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 238000009396 hybridization Methods 0.000 description 1
- 238000003384 imaging method Methods 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 230000000984 immunochemical effect Effects 0.000 description 1
- 238000012606 in vitro cell culture Methods 0.000 description 1
- 231100000253 induce tumour Toxicity 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 229910052740 iodine Inorganic materials 0.000 description 1
- 108010029560 keratinocyte growth factor receptor Proteins 0.000 description 1
- 210000005228 liver tissue Anatomy 0.000 description 1
- 230000004807 localization Effects 0.000 description 1
- 210000004880 lymph fluid Anatomy 0.000 description 1
- 210000003563 lymphoid tissue Anatomy 0.000 description 1
- 239000006249 magnetic particle Substances 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000011987 methylation Effects 0.000 description 1
- 238000007069 methylation reaction Methods 0.000 description 1
- 235000013336 milk Nutrition 0.000 description 1
- 210000004080 milk Anatomy 0.000 description 1
- 239000008267 milk Substances 0.000 description 1
- 210000000822 natural killer cell Anatomy 0.000 description 1
- 229940124276 oligodeoxyribonucleotide Drugs 0.000 description 1
- 150000002482 oligosaccharides Polymers 0.000 description 1
- 231100000590 oncogenic Toxicity 0.000 description 1
- 230000002246 oncogenic effect Effects 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 210000004923 pancreatic tissue Anatomy 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 210000002381 plasma Anatomy 0.000 description 1
- 229920000729 poly(L-lysine) polymer Polymers 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 108020001213 potassium channel Proteins 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 239000002987 primer (paints) Substances 0.000 description 1
- 230000010469 pro-virus integration Effects 0.000 description 1
- 238000004393 prognosis Methods 0.000 description 1
- 230000000750 progressive effect Effects 0.000 description 1
- 235000019419 proteases Nutrition 0.000 description 1
- 108020000494 protein-tyrosine phosphatase Proteins 0.000 description 1
- 230000002285 radioactive effect Effects 0.000 description 1
- 238000001959 radiotherapy Methods 0.000 description 1
- 238000010188 recombinant method Methods 0.000 description 1
- 210000005084 renal tissue Anatomy 0.000 description 1
- 230000000241 respiratory effect Effects 0.000 description 1
- 230000001177 retroviral effect Effects 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 239000002336 ribonucleotide Substances 0.000 description 1
- 125000002652 ribonucleotide group Chemical group 0.000 description 1
- 108091092562 ribozyme Proteins 0.000 description 1
- 229960004641 rituximab Drugs 0.000 description 1
- 210000003296 saliva Anatomy 0.000 description 1
- 229910000077 silane Inorganic materials 0.000 description 1
- PVGBHEUCHKGFQP-UHFFFAOYSA-N sodium;n-[5-amino-2-(4-aminophenyl)sulfonylphenyl]sulfonylacetamide Chemical compound [Na+].CC(=O)NS(=O)(=O)C1=CC(N)=CC=C1S(=O)(=O)C1=CC=C(N)C=C1 PVGBHEUCHKGFQP-UHFFFAOYSA-N 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000007790 solid phase Substances 0.000 description 1
- 210000001082 somatic cell Anatomy 0.000 description 1
- 230000037439 somatic mutation Effects 0.000 description 1
- 230000002269 spontaneous effect Effects 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 210000001138 tear Anatomy 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 201000003896 thanatophoric dysplasia Diseases 0.000 description 1
- 231100000167 toxic agent Toxicity 0.000 description 1
- 239000003440 toxic substance Substances 0.000 description 1
- 231100000041 toxicology testing Toxicity 0.000 description 1
- 239000003053 toxin Substances 0.000 description 1
- 231100000765 toxin Toxicity 0.000 description 1
- 108700012359 toxins Proteins 0.000 description 1
- 230000005945 translocation Effects 0.000 description 1
- 230000005740 tumor formation Effects 0.000 description 1
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 1
- 235000002374 tyrosine Nutrition 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
- C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/136—Screening for pharmacological compounds
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/158—Expression markers
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Zoology (AREA)
- Genetics & Genomics (AREA)
- Pathology (AREA)
- Analytical Chemistry (AREA)
- Wood Science & Technology (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Physics & Mathematics (AREA)
- Hospice & Palliative Care (AREA)
- Biochemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Engineering & Computer Science (AREA)
- Oncology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- General Chemical & Material Sciences (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Investigating Or Analysing Biological Materials (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US66986105P | 2005-04-07 | 2005-04-07 | |
| US60/669,861 | 2005-04-07 | ||
| PCT/US2006/013153 WO2006110581A2 (en) | 2005-04-07 | 2006-04-07 | Cancer-related genes |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA2604844A1 true CA2604844A1 (en) | 2006-10-19 |
Family
ID=36809257
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA002604844A Abandoned CA2604844A1 (en) | 2005-04-07 | 2006-04-07 | Cancer-related genes |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US20090220495A1 (cg-RX-API-DMAC7.html) |
| EP (3) | EP1910557A2 (cg-RX-API-DMAC7.html) |
| JP (2) | JP2008535494A (cg-RX-API-DMAC7.html) |
| AU (1) | AU2006235258A1 (cg-RX-API-DMAC7.html) |
| CA (1) | CA2604844A1 (cg-RX-API-DMAC7.html) |
| WO (2) | WO2006110581A2 (cg-RX-API-DMAC7.html) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9994912B2 (en) | 2014-07-03 | 2018-06-12 | Abbott Molecular Inc. | Materials and methods for assessing progression of prostate cancer |
Families Citing this family (69)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2555185C (en) | 2004-02-06 | 2020-03-24 | Morphosys Ag | Anti-cd38 human antibodies and uses therefor |
| US9200061B2 (en) | 2004-02-06 | 2015-12-01 | Morpho Sys AG | Generation and profiling of fully human HuCAL gold®-derived therapeutic antibodies specific for human CD3i |
| AR055191A1 (es) | 2005-10-12 | 2007-08-08 | Morphosys Ag | Generacion y caracterizacion de anticuerpos terapeuticos derivados de hucal- gold totalmente humanos especificos para el cd38 humano |
| EP2412821B1 (en) | 2006-01-11 | 2014-09-17 | Genomic Health, Inc. | AREG as a gene expression marker for colorectal cancer prognosis |
| WO2007134210A2 (en) * | 2006-05-12 | 2007-11-22 | Genentech, Inc. | Methods and compositions for the diagnosis and treatment of cancer |
| EP2032719A2 (en) * | 2006-06-02 | 2009-03-11 | GlaxoSmithKline Biologicals S.A. | Method for identifying whether a patient will be responder or not to immunotherapy |
| US7919092B2 (en) | 2006-06-13 | 2011-04-05 | Oncomed Pharmaceuticals, Inc. | Antibodies to notch receptors |
| CA2932012A1 (en) | 2006-08-18 | 2008-02-21 | Novartis Ag | Prlr-specific antibody and uses thereof |
| JP5618544B2 (ja) | 2007-01-24 | 2014-11-05 | オンコメッドファーマシューティカルズ インコーポレイテッド | 癌の診断および処置のための組成物および方法 |
| CA2680046A1 (en) * | 2007-03-23 | 2008-10-02 | The Translational Genomics Research Institute | Methods of diagnosing, classifying and treating endometrial cancer and precancer |
| ES2442919T3 (es) | 2007-03-27 | 2014-02-14 | Immunovia Ab | Firma/marcadores de proteínas para la detección de adenocarcinoma |
| NZ599214A (en) * | 2007-06-01 | 2013-12-20 | Univ California | Multigene prognostic assay for lung cancer |
| PT2173379E (pt) | 2007-07-02 | 2015-11-24 | Oncomed Pharm Inc | Composições e métodos para o tratamento e diagnóstico de cancro |
| CA2705486C (en) * | 2007-11-19 | 2019-04-02 | Celera Corporation | Lung cancer markers and uses thereof |
| WO2009117018A1 (en) * | 2008-03-20 | 2009-09-24 | Transmolecular, Inc. | Inhibition of angiogenesis |
| WO2009140599A1 (en) | 2008-05-15 | 2009-11-19 | Transmolecular, Inc. | Treatment of metastatic tumors |
| US8187601B2 (en) | 2008-07-01 | 2012-05-29 | Aveo Pharmaceuticals, Inc. | Fibroblast growth factor receptor 3 (FGFR3) binding proteins |
| US9132189B2 (en) | 2008-07-08 | 2015-09-15 | Oncomed Pharmaceuticals, Inc. | Notch1 binding agents and methods of use thereof |
| MX2011000233A (es) | 2008-07-08 | 2011-05-19 | Oncomed Pharm Inc | Agentes de union del receptor notch1 y metodos para su uso. |
| EP2373338B1 (en) * | 2008-12-03 | 2017-02-15 | The Johns Hopkins University | Annexina2 as immunological target |
| NZ596054A (en) | 2009-05-01 | 2013-07-26 | Genomic Health Inc | Gene expression profile algorithm and test for likelihood of recurrence of colorectal cancer and response to chemotherapy |
| CN102958534B (zh) | 2010-01-13 | 2014-11-05 | 昂考梅德药品有限公司 | Notch1结合剂及其使用方法 |
| CN106995493B (zh) | 2010-02-04 | 2021-09-24 | 卫材公司 | 氯毒素多肽和结合物及其应用 |
| EP3165533B1 (en) | 2010-05-11 | 2020-04-08 | Fred Hutchinson Cancer Research Center | Chlorotoxin variants, conjugates and methods for their use |
| EP2600901B1 (en) | 2010-08-06 | 2019-03-27 | ModernaTX, Inc. | A pharmaceutical formulation comprising engineered nucleic acids and medical use thereof |
| MX2013003681A (es) | 2010-10-01 | 2013-11-20 | Moderna Therapeutics Inc | Ácidos nucleicos manipulados y métodos de uso de los mismos. |
| GB201103726D0 (en) | 2011-03-04 | 2011-04-20 | Immunovia Ab | Method, array and use thereof |
| WO2012135805A2 (en) | 2011-03-31 | 2012-10-04 | modeRNA Therapeutics | Delivery and formulation of engineered nucleic acids |
| WO2012136519A1 (en) | 2011-04-06 | 2012-10-11 | Bayer Pharma Aktiengesellschaft | Use of neutralizing prolactin receptor antibodies for the treatment and prevention of antiestrogen-resistant breast cancer |
| EP2530089A1 (en) | 2011-06-03 | 2012-12-05 | Bayer Pharma Aktiengesellschaft | Neutralising prolactin receptor antibody Mat3 and its therapeutical use |
| EP2731625B1 (en) | 2011-07-15 | 2018-04-18 | OncoMed Pharmaceuticals, Inc. | Rspo binding agents and uses thereof |
| US9464124B2 (en) | 2011-09-12 | 2016-10-11 | Moderna Therapeutics, Inc. | Engineered nucleic acids and methods of use thereof |
| WO2013044164A1 (en) * | 2011-09-21 | 2013-03-28 | The Regents Of The University Of California | Methods to treat and/or prevent relapse in notch1-driven malignancies |
| US9428535B2 (en) | 2011-10-03 | 2016-08-30 | Moderna Therapeutics, Inc. | Modified nucleosides, nucleotides, and nucleic acids, and uses thereof |
| SMT202200355T1 (it) | 2011-12-16 | 2022-11-18 | Modernatx Inc | Composizioni di mrna modificato |
| MX366804B (es) * | 2012-02-11 | 2019-07-25 | Genentech Inc | Translocaciones de la r-espondina y sus metodos de uso. |
| US9283287B2 (en) | 2012-04-02 | 2016-03-15 | Moderna Therapeutics, Inc. | Modified polynucleotides for the production of nuclear proteins |
| US9572897B2 (en) | 2012-04-02 | 2017-02-21 | Modernatx, Inc. | Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins |
| US10501512B2 (en) | 2012-04-02 | 2019-12-10 | Modernatx, Inc. | Modified polynucleotides |
| EP2834260A4 (en) | 2012-04-02 | 2016-08-10 | Moderna Therapeutics Inc | MODIFIED POLYNUCLEOTIDES FOR THE PREPARATION OF MEMBRANE PROTEINS |
| WO2013166153A2 (en) * | 2012-05-01 | 2013-11-07 | Brentnall Teri | Methods and compositions for cancer diagnosis |
| KR102082098B1 (ko) * | 2012-05-11 | 2020-02-26 | 국립연구개발법인 고쿠리츠간켄큐센터 | 신장 세포암의 예후 예측방법 |
| CN104854132A (zh) | 2012-07-13 | 2015-08-19 | 昂考梅德药品有限公司 | Rspo3结合剂及其用途 |
| EP2922554B1 (en) | 2012-11-26 | 2022-02-23 | ModernaTX, Inc. | Terminally modified rna |
| BR112015013525A2 (pt) | 2012-12-10 | 2017-11-14 | Hutchinson Fred Cancer Res | método para produção de uma proteína de fusão, bem como composição compreendendo uma proteína de fusão |
| TWI582239B (zh) * | 2013-03-11 | 2017-05-11 | 諾華公司 | 與ｗｎｔ抑制劑相關之標記 |
| US8980864B2 (en) | 2013-03-15 | 2015-03-17 | Moderna Therapeutics, Inc. | Compositions and methods of altering cholesterol levels |
| JP2015008686A (ja) * | 2013-06-28 | 2015-01-19 | 三菱レイヨン株式会社 | 肝臓細胞又はその前駆細胞に由来する細胞の状態を評価する方法、並びに、その方法に用いるプローブ又はプローブセット及びマイクロアレイ |
| US9567641B2 (en) | 2013-07-03 | 2017-02-14 | Samsung Electronics Co., Ltd. | Combination therapy for the treatment of cancer using an anti-C-met antibody |
| WO2015035415A1 (en) | 2013-09-09 | 2015-03-12 | Nantomics, Llc | Method of detecting suceptibility to breast cancer through mutations in the fgfr3 and tp53 genes |
| US11559580B1 (en) | 2013-09-17 | 2023-01-24 | Blaze Bioscience, Inc. | Tissue-homing peptide conjugates and methods of use thereof |
| EP3052106A4 (en) | 2013-09-30 | 2017-07-19 | ModernaTX, Inc. | Polynucleotides encoding immune modulating polypeptides |
| JP2016538829A (ja) | 2013-10-03 | 2016-12-15 | モデルナ セラピューティクス インコーポレイテッドＭｏｄｅｒｎａ Ｔｈｅｒａｐｅｕｔｉｃｓ，Ｉｎｃ． | 低密度リポタンパク質受容体をコードするポリヌクレオチド |
| GB201319878D0 (en) * | 2013-11-11 | 2013-12-25 | Immunovia Ab | Method, Array and use thereof |
| ES2902835T3 (es) | 2014-01-09 | 2022-03-30 | Hadasit Med Res Service | Composiciones celulares mejoradas y métodos para la terapia contra el cáncer |
| MA40574A (fr) | 2014-09-16 | 2016-03-24 | Oncomed Pharm Inc | Traitement de maladies fibrotiques |
| WO2017020026A1 (en) | 2015-07-30 | 2017-02-02 | Modernatx, Inc. | Concatemeric peptide epitopes rnas |
| CA3021011A1 (en) | 2016-04-15 | 2017-10-19 | Blaze Bioscience, Inc. | Methods of treating breast cancer |
| US12421556B2 (en) | 2017-08-10 | 2025-09-23 | The Institute Of Cancer Research: Royal Cancer Hospital | Materials and methods for stratifying and treating cancers |
| WO2019112489A1 (en) * | 2017-12-05 | 2019-06-13 | Limited Liability Company "Gero" | Methods and agents for treatment of aging and aging related conditions and diseases |
| US11834487B2 (en) | 2018-02-12 | 2023-12-05 | Hadasit Medical Research Services & Development Ltd. | Modulation of SLAMF6 splice variants for cancer therapy |
| KR101890392B1 (ko) * | 2018-05-28 | 2018-08-21 | 의료법인 성광의료재단 | Ｗｎｔ３ａ를 포함하는 난소암의 진단을 위한 마커 및 조성물 |
| KR20200115883A (ko) * | 2019-03-28 | 2020-10-08 | 황인후 | 테트라스파닌-2 억제제를 유효성분으로 포함하는 췌장암 예방, 개선 또는 치료용 조성물 |
| KR102169901B1 (ko) * | 2019-05-17 | 2020-10-26 | 연세대학교 산학협력단 | Dna 메틸화를 이용한 면역 항암 요법의 치료 반응에 관한 정보 제공 방법 및 이를 이용한 키트 |
| US20220326243A1 (en) * | 2019-05-21 | 2022-10-13 | Acurasysbio Co., Ltd. | Composition for cancer diagnosis |
| IL267614A (en) * | 2019-06-24 | 2019-09-26 | Lotem Michal | Nucleic acids to modulate SLAMF6 isoforms |
| IL294280A (en) * | 2019-12-25 | 2022-08-01 | Shanghai Xbh Biotechnology Co Ltd | Compositions and methods for treating autoimmune diseases and cancers by targeting igsf8 |
| GB202010970D0 (en) | 2020-07-16 | 2020-09-02 | Immunovia Ab | Methods, arrays and uses thereof |
| CN114487418A (zh) | 2022-02-17 | 2022-05-13 | 温州医科大学附属第二医院（温州医科大学附属育英儿童医院） | TGFb RIII蛋白作为胃癌血清生物标志物的应用 |
Family Cites Families (131)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4179337A (en) | 1973-07-20 | 1979-12-18 | Davis Frank F | Non-immunogenic polypeptides |
| US4275149A (en) | 1978-11-24 | 1981-06-23 | Syva Company | Macromolecular environment control in specific receptor assays |
| JPS6023084B2 (ja) | 1979-07-11 | 1985-06-05 | 味の素株式会社 | 代用血液 |
| WO1981001145A1 (en) | 1979-10-18 | 1981-04-30 | Univ Illinois | Hydrolytic enzyme-activatible pro-drugs |
| US4640835A (en) | 1981-10-30 | 1987-02-03 | Nippon Chemiphar Company, Ltd. | Plasminogen activator derivatives |
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| US4675187A (en) | 1983-05-16 | 1987-06-23 | Bristol-Myers Company | BBM-1675, a new antibiotic complex |
| US4496689A (en) | 1983-12-27 | 1985-01-29 | Miles Laboratories, Inc. | Covalently attached complex of alpha-1-proteinase inhibitor with a water soluble polymer |
| US4753894A (en) | 1984-02-08 | 1988-06-28 | Cetus Corporation | Monoclonal anti-human breast cancer antibodies |
| US5430136A (en) | 1984-10-16 | 1995-07-04 | Chiron Corporation | Oligonucleotides having selectably cleavable and/or abasic sites |
| US4959314A (en) | 1984-11-09 | 1990-09-25 | Cetus Corporation | Cysteine-depleted muteins of biologically active proteins |
| US4683202A (en) | 1985-03-28 | 1987-07-28 | Cetus Corporation | Process for amplifying nucleic acid sequences |
| US4683195A (en) | 1986-01-30 | 1987-07-28 | Cetus Corporation | Process for amplifying, detecting, and/or-cloning nucleic acid sequences |
| US4737456A (en) | 1985-05-09 | 1988-04-12 | Syntex (U.S.A.) Inc. | Reducing interference in ligand-receptor binding assays |
| EP0206448B1 (en) | 1985-06-19 | 1990-11-14 | Ajinomoto Co., Inc. | Hemoglobin combined with a poly(alkylene oxide) |
| US4777127A (en) | 1985-09-30 | 1988-10-11 | Labsystems Oy | Human retrovirus-related products and methods of diagnosing and treating conditions associated with said retrovirus |
| US4938948A (en) | 1985-10-07 | 1990-07-03 | Cetus Corporation | Method for imaging breast tumors using labeled monoclonal anti-human breast cancer antibodies |
| US4956453A (en) | 1985-12-06 | 1990-09-11 | Cetus Corporation | Anti-human ovarian cancer immunotoxins and methods of use thereof |
| US4868105A (en) | 1985-12-11 | 1989-09-19 | Chiron Corporation | Solution phase nucleic acid sandwich assay |
| EP0272253A4 (en) | 1986-03-07 | 1990-02-05 | Massachusetts Inst Technology | METHOD FOR IMPROVING GLYCOPROTE INSTABILITY. |
| US4791192A (en) | 1986-06-26 | 1988-12-13 | Takeda Chemical Industries, Ltd. | Chemically modified protein with polyethyleneglycol |
| GB8702816D0 (en) | 1987-02-07 | 1987-03-11 | Al Sumidaie A M K | Obtaining retrovirus-containing fraction |
| US5219740A (en) | 1987-02-13 | 1993-06-15 | Fred Hutchinson Cancer Research Center | Retroviral gene transfer into diploid fibroblasts for gene therapy |
| GB8705477D0 (en) | 1987-03-09 | 1987-04-15 | Carlton Med Prod | Drug delivery systems |
| US4975278A (en) | 1988-02-26 | 1990-12-04 | Bristol-Myers Company | Antibody-enzyme conjugates in combination with prodrugs for the delivery of cytotoxic agents to tumor cells |
| US5359100A (en) | 1987-10-15 | 1994-10-25 | Chiron Corporation | Bifunctional blocked phosphoramidites useful in making nucleic acid mutimers |
| US5124246A (en) | 1987-10-15 | 1992-06-23 | Chiron Corporation | Nucleic acid multimers and amplified nucleic acid hybridization assays using same |
| US5206152A (en) | 1988-04-08 | 1993-04-27 | Arch Development Corporation | Cloning and expression of early growth regulatory protein genes |
| US5700637A (en) | 1988-05-03 | 1997-12-23 | Isis Innovation Limited | Apparatus and method for analyzing polynucleotide sequences and method of generating oligonucleotide arrays |
| US5422120A (en) | 1988-05-30 | 1995-06-06 | Depotech Corporation | Heterovesicular liposomes |
| AP129A (en) | 1988-06-03 | 1991-04-17 | Smithkline Biologicals S A | Expression of retrovirus gag protein eukaryotic cells |
| GB8823869D0 (en) | 1988-10-12 | 1988-11-16 | Medical Res Council | Production of antibodies |
| US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| JP2752788B2 (ja) | 1989-01-23 | 1998-05-18 | カイロン コーポレイション | 感染および過剰増殖障害の為の組換え療法 |
| JPH04503957A (ja) | 1989-03-07 | 1992-07-16 | ジェネンテク，インコーポレイテッド | 脂質とオリゴヌクレオチドの共有結合コンジュゲート |
| DK0737750T3 (da) | 1989-03-21 | 2003-09-01 | Vical Inc | Ekspression af exogene polynucleotidsekvenser i vertebrater |
| US5703055A (en) | 1989-03-21 | 1997-12-30 | Wisconsin Alumni Research Foundation | Generation of antibodies through lipid mediated DNA delivery |
| US5143854A (en) | 1989-06-07 | 1992-09-01 | Affymax Technologies N.V. | Large scale photolithographic solid phase synthesis of polypeptides and receptor binding screening thereof |
| US6040138A (en) | 1995-09-15 | 2000-03-21 | Affymetrix, Inc. | Expression monitoring by hybridization to high density oligonucleotide arrays |
| AU648261B2 (en) | 1989-08-18 | 1994-04-21 | Novartis Vaccines And Diagnostics, Inc. | Recombinant retroviruses delivering vector constructs to target cells |
| US5585362A (en) | 1989-08-22 | 1996-12-17 | The Regents Of The University Of Michigan | Adenovirus vectors for gene therapy |
| WO1991004753A1 (en) | 1989-10-02 | 1991-04-18 | Cetus Corporation | Conjugates of antisense oligonucleotides and therapeutic uses thereof |
| ATE139258T1 (de) | 1990-01-12 | 1996-06-15 | Cell Genesys Inc | Erzeugung xenogener antikörper |
| ZA911974B (en) | 1990-03-21 | 1994-08-22 | Res Dev Foundation | Heterovesicular liposomes |
| US5470967A (en) | 1990-04-10 | 1995-11-28 | The Dupont Merck Pharmaceutical Company | Oligonucleotide analogs with sulfamate linkages |
| US5149655A (en) | 1990-06-21 | 1992-09-22 | Agracetus, Inc. | Apparatus for genetic transformation |
| AU8412991A (en) | 1990-07-27 | 1992-03-02 | Chiron Corporation | Large comb-type branched polynucleotides |
| AU8507191A (en) | 1990-08-29 | 1992-03-30 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
| US5633425A (en) | 1990-08-29 | 1997-05-27 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
| US5545806A (en) | 1990-08-29 | 1996-08-13 | Genpharm International, Inc. | Ransgenic non-human animals for producing heterologous antibodies |
| US5625126A (en) | 1990-08-29 | 1997-04-29 | Genpharm International, Inc. | Transgenic non-human animals for producing heterologous antibodies |
| US5661016A (en) | 1990-08-29 | 1997-08-26 | Genpharm International Inc. | Transgenic non-human animals capable of producing heterologous antibodies of various isotypes |
| CA2098849C (en) | 1990-12-20 | 2007-07-10 | Ralph R. Weichselbaum | Control of gene expression by ionizing radiation |
| EP0519596B1 (en) | 1991-05-17 | 2005-02-23 | Merck & Co. Inc. | A method for reducing the immunogenicity of antibody variable domains |
| US5714331A (en) | 1991-05-24 | 1998-02-03 | Buchardt, Deceased; Ole | Peptide nucleic acids having enhanced binding affinity, sequence specificity and solubility |
| US5419966A (en) | 1991-06-10 | 1995-05-30 | Microprobe Corporation | Solid support for synthesis of 3'-tailed oligonucleotides |
| US5264586A (en) | 1991-07-17 | 1993-11-23 | The Scripps Research Institute | Analogs of calicheamicin gamma1I, method of making and using the same |
| ATE237694T1 (de) | 1991-08-20 | 2003-05-15 | Us Gov Health & Human Serv | Adenovirus vermittelter gentransfer in den gastrointestinaltrakt |
| WO1993010218A1 (en) | 1991-11-14 | 1993-05-27 | The United States Government As Represented By The Secretary Of The Department Of Health And Human Services | Vectors including foreign genes and negative selective markers |
| US5384261A (en) | 1991-11-22 | 1995-01-24 | Affymax Technologies N.V. | Very large scale immobilized polymer synthesis using mechanically directed flow paths |
| GB9125623D0 (en) | 1991-12-02 | 1992-01-29 | Dynal As | Cell modification |
| CA2103887C (en) | 1991-12-13 | 2005-08-30 | Gary M. Studnicka | Methods and materials for preparation of modified antibody variable domains and therapeutic uses thereof |
| WO1993014778A1 (en) | 1992-01-23 | 1993-08-05 | Vical, Inc. | Ex vivo gene transfer |
| FR2688514A1 (fr) | 1992-03-16 | 1993-09-17 | Centre Nat Rech Scient | Adenovirus recombinants defectifs exprimant des cytokines et medicaments antitumoraux les contenant. |
| ZA932522B (en) | 1992-04-10 | 1993-12-20 | Res Dev Foundation | Immunotoxins directed against c-erbB-2(HER/neu) related surface antigens |
| AU4115693A (en) | 1992-04-24 | 1993-11-29 | Sri International | In vivo homologous sequence targeting in eukaryotic cells |
| JPH07507689A (ja) | 1992-06-08 | 1995-08-31 | ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア | 特定組織のターゲティング方法及び組成物 |
| JPH09507741A (ja) | 1992-06-10 | 1997-08-12 | アメリカ合衆国 | ヒト血清による不活性化に耐性のあるベクター粒子 |
| ATE381614T1 (de) | 1992-07-24 | 2008-01-15 | Amgen Fremont Inc | Bildung von xenogenen antikörpern |
| GB2269175A (en) | 1992-07-31 | 1994-02-02 | Imperial College | Retroviral vectors |
| DK0752248T3 (da) | 1992-11-13 | 2000-11-13 | Idec Pharma Corp | Terapeutisk anvendelse af kimæriske og radioaktivt mærkede antistoffer mod humant B-lymfocytbegrænset differentieringsantig |
| AU680459B2 (en) | 1992-12-03 | 1997-07-31 | Genzyme Corporation | Gene therapy for cystic fibrosis |
| US5759573A (en) | 1993-04-22 | 1998-06-02 | Depotech Corporation | Cyclodextrin liposomes encapsulating pharmacologic compounds and methods for their use |
| DE69434486T2 (de) | 1993-06-24 | 2006-07-06 | Advec Inc. | Adenovirus vektoren für gentherapie |
| US5837832A (en) | 1993-06-25 | 1998-11-17 | Affymetrix, Inc. | Arrays of nucleic acid probes on biological chips |
| US6015686A (en) | 1993-09-15 | 2000-01-18 | Chiron Viagene, Inc. | Eukaryotic layered vector initiation systems |
| ATE440957T1 (de) | 1993-09-15 | 2009-09-15 | Novartis Vaccines & Diagnostic | Rekombinante alphavirus vektoren |
| BR9407956A (pt) | 1993-10-25 | 1996-11-26 | Canji Inc | Composiçao farmacêutica vetor de express o de adenovirus recombinante e kit par reduzir a proliferaçao de células tumorais |
| CN1099868C (zh) | 1993-11-16 | 2003-01-29 | 斯卡法玛公司 | 具有控制释放活性成分作用的囊 |
| US5681697A (en) | 1993-12-08 | 1997-10-28 | Chiron Corporation | Solution phase nucleic acid sandwich assays having reduced background noise and kits therefor |
| US6015880A (en) | 1994-03-16 | 2000-01-18 | California Institute Of Technology | Method and substrate for performing multiple sequential reactions on a matrix |
| WO1995030763A2 (en) | 1994-05-09 | 1995-11-16 | Chiron Viagene, Inc. | Retroviral vectors having a reduced recombination rate |
| US5773001A (en) | 1994-06-03 | 1998-06-30 | American Cyanamid Company | Conjugates of methyltrithio antitumor agents and intermediates for their synthesis |
| US5807522A (en) | 1994-06-17 | 1998-09-15 | The Board Of Trustees Of The Leland Stanford Junior University | Methods for fabricating microarrays of biological samples |
| US5580731A (en) | 1994-08-25 | 1996-12-03 | Chiron Corporation | N-4 modified pyrimidine deoxynucleotides and oligonucleotide probes synthesized therewith |
| US5597909A (en) | 1994-08-25 | 1997-01-28 | Chiron Corporation | Polynucleotide reagents containing modified deoxyribose moieties, and associated methods of synthesis and use |
| US5681702A (en) | 1994-08-30 | 1997-10-28 | Chiron Corporation | Reduction of nonspecific hybridization by using novel base-pairing schemes |
| WO1996017072A2 (en) | 1994-11-30 | 1996-06-06 | Chiron Viagene, Inc. | Recombinant alphavirus vectors |
| US6130364A (en) | 1995-03-29 | 2000-10-10 | Abgenix, Inc. | Production of antibodies using Cre-mediated site-specific recombination |
| AU5632296A (en) | 1995-04-27 | 1996-11-18 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
| US5714586A (en) | 1995-06-07 | 1998-02-03 | American Cyanamid Company | Methods for the preparation of monomeric calicheamicin derivative/carrier conjugates |
| US5712374A (en) | 1995-06-07 | 1998-01-27 | American Cyanamid Company | Method for the preparation of substantiallly monomeric calicheamicin derivative/carrier conjugates |
| JP2001509661A (ja) | 1996-01-23 | 2001-07-24 | ザ ボード オブ トラスティーズ オブ ザ リーランド スタンフォード ジュニア ユニバーシティ | トランス支配性細胞内作用因子ペプチドおよびｒｎａ分子のスクリーニング方法 |
| EP0953052B1 (en) | 1996-05-06 | 2009-03-04 | Oxford BioMedica (UK) Limited | Crossless retroviral vectors |
| US5980898A (en) | 1996-11-14 | 1999-11-09 | The United States Of America As Represented By The U.S. Army Medical Research & Material Command | Adjuvant for transcutaneous immunization |
| EP2305027B1 (en) | 1996-12-03 | 2014-07-02 | Amgen Fremont Inc. | Transgenic mammals having human Ig loci including plural VH and Vkappa regions and antibodies produced therefrom |
| US6506559B1 (en) | 1997-12-23 | 2003-01-14 | Carnegie Institute Of Washington | Genetic inhibition by double-stranded RNA |
| PT1071700E (pt) | 1998-04-20 | 2010-04-23 | Glycart Biotechnology Ag | Modificação por glicosilação de anticorpos para melhorar a citotoxicidade celular dependente de anticorpos |
| DE19956568A1 (de) | 1999-01-30 | 2000-08-17 | Roland Kreutzer | Verfahren und Medikament zur Hemmung der Expression eines vorgegebenen Gens |
| EP2278003B2 (en) | 1999-04-09 | 2020-08-05 | Kyowa Kirin Co., Ltd. | Method for controlling the activity of immunologically functional molecule |
| JP2003516124A (ja) | 1999-10-15 | 2003-05-13 | ユニバーシティー オブ マサチューセッツ | 標的とした遺伝的干渉の手段としてのｒｎａ干渉経路遺伝子 |
| US6475220B1 (en) | 1999-10-15 | 2002-11-05 | Whiteside Biomechanics, Inc. | Spinal cable system |
| GB9927444D0 (en) | 1999-11-19 | 2000-01-19 | Cancer Res Campaign Tech | Inhibiting gene expression |
| US6406840B1 (en) | 1999-12-17 | 2002-06-18 | Biomosaic Systems, Inc. | Cell arrays and the uses thereof |
| DE10019058A1 (de) * | 2000-04-06 | 2001-12-20 | Epigenomics Ag | Detektion von Variationen des DNA-Methylierungsprofils |
| AU2002229099A1 (en) * | 2000-12-18 | 2002-07-01 | Genaissance Pharmaceuticals, Inc. | Haplotypes of the prlr gene |
| US7645441B2 (en) * | 2000-12-22 | 2010-01-12 | Sagres Discovery Inc. | Compositions and methods in cancer associated with altered expression of PRLR |
| US7754208B2 (en) | 2001-01-17 | 2010-07-13 | Trubion Pharmaceuticals, Inc. | Binding domain-immunoglobulin fusion proteins |
| US20030133939A1 (en) | 2001-01-17 | 2003-07-17 | Genecraft, Inc. | Binding domain-immunoglobulin fusion proteins |
| WO2003008583A2 (en) * | 2001-03-02 | 2003-01-30 | Sagres Discovery | Novel compositions and methods for cancer |
| US6884869B2 (en) | 2001-04-30 | 2005-04-26 | Seattle Genetics, Inc. | Pentapeptide compounds and uses related thereto |
| US7713526B2 (en) * | 2001-05-01 | 2010-05-11 | The Regents Of The University Of California | Wnt and frizzled receptors as targets for immunotherapy in head and neck squamous cell carcinomas |
| US6441163B1 (en) | 2001-05-31 | 2002-08-27 | Immunogen, Inc. | Methods for preparation of cytotoxic conjugates of maytansinoids and cell binding agents |
| US7705120B2 (en) * | 2001-06-21 | 2010-04-27 | Millennium Pharmaceuticals, Inc. | Compositions, kits, and methods for identification, assessment, prevention, and therapy of breast cancer |
| US7074175B2 (en) | 2001-07-25 | 2006-07-11 | Erik Schroeder Handy | Thermotherapy via targeted delivery of nanoscale magnetic particles |
| US6997863B2 (en) | 2001-07-25 | 2006-02-14 | Triton Biosystems, Inc. | Thermotherapy via targeted delivery of nanoscale magnetic particles |
| WO2003026577A2 (en) | 2001-09-24 | 2003-04-03 | Seattle Genetics, Inc. | P-amidobenzylethers in drug delivery agents |
| EP1466016A2 (en) * | 2002-01-09 | 2004-10-13 | Riken Institute Of Physical And Chemical Research | Cancer profiles |
| US7317091B2 (en) | 2002-03-01 | 2008-01-08 | Xencor, Inc. | Optimized Fc variants |
| DK1513934T3 (da) * | 2002-06-06 | 2011-05-02 | Oncotherapy Science Inc | Gener og polypeptider relateret til humane coloncancersygdomme |
| WO2004016317A1 (en) * | 2002-08-14 | 2004-02-26 | Erasmus University Medical Center Rotterdam | Use of murine genomic regions identified to be involved in tumor development for the development of anti-cancer drugs and diagnosis of cancer |
| AU2004240541B2 (en) | 2003-05-20 | 2009-08-20 | Immunogen, Inc. | Improved cytotoxic agents comprising new maytansinoids |
| US7640114B2 (en) * | 2003-05-21 | 2009-12-29 | The Wistar Institute Of Anatomy & Biology | Method of diagnosis of cancer based on gene expression profiles in cells |
| CA2527321A1 (en) * | 2003-05-30 | 2004-12-23 | Genomic Health, Inc. | Gene expression markers for response to egfr inhibitor drugs |
| WO2005005601A2 (en) * | 2003-06-09 | 2005-01-20 | The Regents Of The University Of Michigan | Compositions and methods for treating and diagnosing cancer |
| WO2005001126A1 (en) * | 2003-06-12 | 2005-01-06 | Korea Research Institute Of Bioscience And Biotechnology | Detection kit for gastric cancer and metastatic gastric cancer |
| DE602004017726D1 (de) | 2003-06-30 | 2008-12-24 | Domantis Ltd | Pegylierte Single-domain-antikörper (dAb) |
| JP2005073548A (ja) * | 2003-08-29 | 2005-03-24 | National Cancer Center-Japan | 卵巣明細胞腺癌の検査、治療、および治療薬のスクリーニングのための、ＨＮＦ−１βの利用 |
| US20070054849A1 (en) * | 2003-09-24 | 2007-03-08 | Oncotherapy Science, Inc. | Method for diagnosing hepatocellular carcinomas |
| WO2005077981A2 (en) | 2003-12-22 | 2005-08-25 | Xencor, Inc. | Fc POLYPEPTIDES WITH NOVEL Fc LIGAND BINDING SITES |
| CA2580803C (en) * | 2004-09-21 | 2016-06-14 | Rhode Island Hospital, A Lifespan-Partner | Wnt proteins and detection and treatment of cancer |
-
2006
- 2006-04-07 JP JP2008505603A patent/JP2008535494A/ja active Pending
- 2006-04-07 CA CA002604844A patent/CA2604844A1/en not_active Abandoned
- 2006-04-07 EP EP06749562A patent/EP1910557A2/en not_active Withdrawn
- 2006-04-07 EP EP09001181A patent/EP2083088A3/en not_active Withdrawn
- 2006-04-07 JP JP2008505600A patent/JP2008535853A/ja active Pending
- 2006-04-07 US US11/910,837 patent/US20090220495A1/en not_active Abandoned
- 2006-04-07 EP EP06749567A patent/EP1871911A2/en not_active Ceased
- 2006-04-07 WO PCT/US2006/013153 patent/WO2006110581A2/en not_active Ceased
- 2006-04-07 AU AU2006235258A patent/AU2006235258A1/en not_active Abandoned
- 2006-04-07 WO PCT/US2006/013160 patent/WO2006110585A2/en not_active Ceased
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9994912B2 (en) | 2014-07-03 | 2018-06-12 | Abbott Molecular Inc. | Materials and methods for assessing progression of prostate cancer |
| EP3530751A1 (en) | 2014-07-03 | 2019-08-28 | Abbott Molecular Inc. | Materials and methods for assessing progression of prostate cancer |
| US10604812B2 (en) | 2014-07-03 | 2020-03-31 | Abbott Molecular Inc. | Materials and methods for assessing progression of prostate cancer |
Also Published As
| Publication number | Publication date |
|---|---|
| WO2006110585A3 (en) | 2006-12-21 |
| WO2006110585A2 (en) | 2006-10-19 |
| WO2006110581A2 (en) | 2006-10-19 |
| JP2008535853A (ja) | 2008-09-04 |
| EP2083088A2 (en) | 2009-07-29 |
| AU2006235258A1 (en) | 2006-10-19 |
| WO2006110581A3 (en) | 2007-07-12 |
| EP1871911A2 (en) | 2008-01-02 |
| JP2008535494A (ja) | 2008-09-04 |
| EP1910557A2 (en) | 2008-04-16 |
| EP2083088A3 (en) | 2009-10-14 |
| US20090220495A1 (en) | 2009-09-03 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA2604844A1 (en) | Cancer-related genes | |
| US20070237770A1 (en) | Novel compositions and methods in cancer | |
| EP2062591A1 (en) | CACNA1E in cancer diagnosis detection and treatment | |
| US20080039413A1 (en) | Novel compositions and methods in cancer | |
| AU2004276821A1 (en) | Novel therapeutic targets in cancer | |
| CA2564131A1 (en) | Novel therapeutic targets in cancer | |
| US7919246B2 (en) | SEMA4D in cancer diagnosis, detection and treatment | |
| US20070098728A1 (en) | Novel compositions and methods in cancer | |
| JP4942219B2 (ja) | 癌の診断、検出および処置におけるｄｄｒ２ | |
| US20090297507A1 (en) | ADAM10 in Cancer Diagnosis, Detection and Treatment | |
| AU2005240070A1 (en) | Novel compositions and methods in cancer | |
| EP2204376A2 (en) | Novel therapeutic targets in cancer | |
| US20090317391A1 (en) | Cancer Related Genes (PTPE) | |
| CA2572509A1 (en) | Novel compositions and methods in cancer |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FZDE | Dead |